Hepatitis Delta (HDV)

Home»Hepatitis Delta (HDV)
12 11, 2019

Eiger Announces Peginterferon Lambda – Lonafarnib Combination Interim Results

2019-11-12T21:55:21+00:00

Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019 53% of Patients Achieve Undetectable or BLOQ HDV RNA at Week 24 Median Decline of HDV RNA: -3.4 Log at Week 24 95% of Patients Achieve > [...]

Eiger Announces Peginterferon Lambda – Lonafarnib Combination Interim Results2019-11-12T21:55:21+00:00
28 09, 2019

Eiger to Present at Cantor 2019 Global Healthcare Conference

2019-09-28T15:38:30+00:00

Eiger to Present at Cantor 2019 Global Healthcare Conference PALO ALTO, Calif. – September 27, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Cantor 2019 Global Healthcare Conference on October [...]

Eiger to Present at Cantor 2019 Global Healthcare Conference2019-09-28T15:38:30+00:00
20 08, 2019

Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection

2019-08-20T12:48:11+00:00

Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection Fourth Eiger Program Granted Breakthrough Therapy Designation PALO ALTO, Calif., August 20, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food and [...]

Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection2019-08-20T12:48:11+00:00
5 06, 2019

Eiger Appoints Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA, Vice President of Global HDV Clinical Development

2019-06-05T15:04:41+00:00

Eiger Appoints Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA, Vice President of Global HDV Clinical Development PALO ALTO, Calif., June 5, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA as Vice President of Global [...]

Eiger Appoints Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA, Vice President of Global HDV Clinical Development2019-06-05T15:04:41+00:00
11 04, 2019

Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019

2019-04-11T21:56:39+00:00

Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019 Improved Tolerability in HDV-infected Patients vs Historical Peginterferon Alfa Post-treatment Endpoint Results to be Discussed with Regulatory Agencies PALO ALTO, Calif., April 11, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused [...]

Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 20192019-04-11T21:56:39+00:00
6 02, 2019

Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan

2019-02-06T18:39:19+00:00

Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan Expanded Patent Portfolio Now Includes U.S., Europe and Japan PALO ALTO, Calif., February 6, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare [...]

Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan2019-02-06T18:39:19+00:00
18 12, 2018

Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection

2018-12-18T15:15:54+00:00

Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection Phase 3 HDV “D-LIVR” International Study Initiating PALO ALTO, Calif., December 18, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced the European [...]

Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection2018-12-18T15:15:54+00:00
17 12, 2018

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection

2018-12-17T17:00:35+00:00

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection - Phase 3 HDV “D-LIVR” International Study Initiating PALO ALTO, Calif., December 17, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the [...]

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection2018-12-17T17:00:35+00:00
17 10, 2018

Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection

2018-10-17T20:58:12+00:00

Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection Lambda Antiviral Activity Demonstrated in HDV Infection Currently Dosing Lambda in Combination with Lonafarnib in HDV Infection PALO ALTO, Calif., October 17, 2018 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced positive [...]

Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection2018-10-17T20:58:12+00:00
24 09, 2018

Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018

2018-09-24T18:58:05+00:00

Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018 D-LIVR Study: First-Ever Registration Study for Chronic HDV Infection PALO ALTO, Calif., September 24, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced the receipt [...]

Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 20182018-09-24T18:58:05+00:00